Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
medicare
3
×
national
national blog main
national top stories
3
×
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
3
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
bristol-myers squibb
cancer
cell therapy
clinical trials
crispr
diagnostics
digital health
gene therapy
glaxosmithkline
immunotherapy
What
bio
new
3
×
roundup
drug
remains
advantages
allogene
approval
bar
biogen’s
biopharmaceutical
brings
cancer
companies
convo
crispr
diversity
earlier
expect
failures
gamble
hot
immunotherapy
investors
ipo
juno
littered
market
medco’s
million
mover
nash
nearly
news
patients
payers
physicians
plan
price
pricing
Language
unset
Current search:
medicare
×
new
×
" seattle blog main "
×
" national top stories "
×
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More